Chemistry:Gemlapodect
From HandWiki
Gemlapodect (INN, USAN; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders.[1][2][3] It is taken orally.[1] The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons.[3] Gemlapodect was originated by Roche and is under development by Noema Pharma.[1][2] As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.[1][2]
See also
- List of investigational Tourette's syndrome drugs
References
- ↑ 1.0 1.1 1.2 1.3 "Noema Pharma". 18 September 2025. https://adisinsight.springer.com/drugs/800061337.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Gemlapodect with Synapse". 10 March 2026. https://synapse.patsnap.com/drug/f7ded38ea2bb493091acf11119c4ed52.
- ↑ 3.0 3.1 "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry 34 (6): 1719–1729. June 2025. doi:10.1007/s00787-024-02637-x. PMID 39714607.
 |  |
